Business
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that it has launched a brokered private placement of a minimum of 23,809,523 units of the Company (each a “Unit”) and up to a maxi
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES","length":88,"tagName":"p"},{"type":"text","content":"SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that it has launched a brokered private placement of a minimum of 23,809,523 units of the Company (each a “Unit”) and up to a maximum of 25,396,825 Units, at a price of C$0.63 per Unit (the “Offering Price”), for minimum gross proceeds of C$15,000,000 and maximum gross proceeds of up to C$16,000,000 (the “LIFE Offering”).","length":614,"tagName":"p"},{"type":"text","content":"Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one-half (½) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share (a “Warrant Share”) at an exercise price of C$0.85 for a period of 24 months from the date of issuance.","length":357,"tagName":"p"},{"type":"text","content":"The LIFE Offering will be conducted on a best-efforts, fully marketed basis by Canaccord Genuity Corp., acting as sole lead agent and sole bookrunner (the “Lead Agent”), on behalf of a syndicate of agents to be formed (collectively with the Lead Agent, the “Agents”).","length":267,"tagName":"p"},{"type":"text","content":"In connection with the LIFE Offering, the Company has agreed to pay the Agents a cash commission of 5.0% of the gross proceeds of the LIFE Offering, and to issue Agents’ warrants equal to 5.0% of the number of Units sold under the LIFE Offering, each Agents’ warrant exercisable for one Common Share at the Offering Price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the President’s List up to a maximum of C$5,000,000 will be subject to reduced compensation of 2.5% cash commission and 2.5% Agents’ warrants. In addition, the Company will pay the Lead Agent a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each ...